Cyrus Biotechnology Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article highlighting the exciting potential of decoy receptor drugs in fighting SARS-CoV-2, and other viral infections – (Science.com)

Share this post